Terms ending in 2029
Every in-force patent on Biogen Ma Inc.'s record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,293,237 | Binding Proteins, Including Antibodies, Antibody Derivatives and Antibody Fragments, That Specifically Bind CD154 and Uses Thereof In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US D741,703 | Package In force · High confidence | Bioverativ Therapeutics Inc. | In force | High confidence | |
| US 8,269,043 | Bicyclic Aryl Sphingosine 1-Phosphate Analogs In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 9,181,191 | Heterobicyclic sphingosine 1-phosphate analogs In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 9,708,353 | Heterobicyclic Sphingosine 1-Phosphate Analogs In force · High confidence | Biogen Ma Inc. | In force | High confidence | |
| US 10,081,646 | Heterobicyclic Sphingosine 1-Phosphate Analogs In force · High confidence | Biogen Ma Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Biogen Ma Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.